A recent study evaluated the efficacy and safety of a novel topical treatment containing xyloglucan, pea proteins, and Opuntia ficus-indica extracts (XPO), in comparison to a standard treatment of calcipotriol 50mcg/betamethasone 0.5mg ointment (CB) in patients with mild-to-moderate plaque psoriasis. Forty-two patients were randomly assigned to receive either XPO or CB for a duration of 28 days, with assessments of disease status conducted at baseline, bi-weekly intervals, and at a final follow-up. Disease severity was measured using the Psoriasis Area and Severity Index (PASI), Physician’s Global Assessment (PGA), and Visual Analog Scale for itching, supplemented by photographic documentation before and after treatment.

The results indicated significant improvements in PASI scores for both treatment groups at each assessment point, with XPO demonstrating a notably higher PASI 50 score improvement compared to CB by the study’s end. Similarly, both treatments effectively reduced PGA scores and itching by the third visit. Notably, XPO not only matched CB in terms of reducing psoriasis symptoms but also exhibited an excellent tolerability profile.

Reference: Veraldi S, Rosca V, Orasan RI, Constantin M, Dodiuk-Gad RP. A Prospective, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of a Cream Containing Xyloglucan, Pea Protein, and Opuntia ficus-indica Extract Versus Calcipotriol/Betamethasone in Adult Patients with Mild-to-moderate Psoriasis. J Clin Aesthet Dermatol. 2024 Mar;17(3):12-17. PMID: 38495550; PMCID: PMC10941852.